Author name: Leonardo Arias

The robotic surgery company, which filed a WARN notice with the state in August, plans for the layoffs to be effective in late October.

Providers are turning to the law’s arbitration process in droves to settle out-of-network claims, one factor fueling spending that could cost consumers down the line.

Massachusetts biopharma workforce growth was fairly flat last year, and R&D and manufacturing employment declined, according to a new MassBio report. BioSpace data further highlight challenges facing the state, showing roughly 2,300 people out of work in 2025 and jobs live on the website falling.

En el ámbito científico actual, el manejo de grandes volúmenes de datos representa uno de los mayores desafíos técnicos para investigadores y centros de estudio. La explosión de información generada por experimentos, simulaciones y observaciones ha cr …

BioSpace did a deep dive into biopharma female executives who navigated difficult markets to lead their companies to high-value exits.

Scott Gottlieb, who served as FDA commissioner during the first Trump administration, wrote in a JAMA editorial that China is speeding drugs to market and could potentially surpass the U.S. in the innovation game.

AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year— was unable to distinguish itself from placebo in a mid-to-late-stage trial of progressive supranuclear palsy.

In a new report from Medscape, physicians say a lack of qualified applicants is hampering efforts to fill open positions. Many worry the situation could get worse over the next decade.

Mike Stuart has been the California Blues giant’s interim CEO since March. Now, he’s officially stepping into the role.

Improving health data exchange is a worthy goal, but the initiative has to overcome challenges like data security, under-resourced providers and slow technology uptake, experts say.